Moffitt Cancer Center’s Dr. Jeffrey Lancet to Lead Malignant Hematology Department

August 23, 2016

TAMPA, Fla. – Moffitt Cancer Center has announced that Dr. Jeffrey Lancet has been named the new Chair and Program Leader for the Department of Malignant Hematology. Lancet has served as interim chair of the department since June 30, 2015.

Lancet has written, authored and published several early phase clinical trials utilizing novel therapies for these diseases and currently serves as the principal investigator for many ongoing trials. Within the field of acute leukemia, he has worked extensively with the National Cancer Institute, the Southwest Oncology Group and the pharmaceutical industry.

“Dr. Lancet’s training and experience reflect excellence in clinical practice and clinical research associated with acute leukemias and myelodysplastic syndromes,” said G. Douglas Letson, M.D., Executive Vice President of Clinical Affairs and Physician-in-Chief at Moffitt. “He has consistently provided strong leadership within Moffitt Cancer Center, serving in many important roles, including Chief of Medicine Services.”

Lancet has a strong national and international reputation. In 2010, he received the NCI-ASCO Clinical Investigator Team Leadership Award and he was recently appointed as a member to the FDA-Oncology Drug Advisory Committee.

“I am thrilled, honored and grateful to assume the role of chair and program leader of the Malignant Hematology Department,” said Lancet. “Our program at Moffitt is already one of the finest in the nation for patient care and research in blood cancers, and I plan to build upon this success in both the clinical and scientific arenas with a variety of new initiatives that ultimately will benefit our patients, some of which include renowned faculty/scientist recruitments, multidisciplinary clinics for the best patient care, and instituting more cutting-edge clinical trials led by Moffitt doctors.”

About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, clinical trials, prevention and cancer control. Moffitt is the No. 6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2.5 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,200 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube

 

###